

How to Cite:

Saroha, A., Verma, A., Dahiya, A., Singh, L., & Garg, R. (2022). An updated review on topical liposomal gel. *International Journal of Health Sciences*, 6(S1), 7475–7491.
<https://doi.org/10.53730/ijhs.v6nS1.6595>

An updated review on topical liposomal gel

Akshay Saroha

University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali
- 140413, India

Anchal Verma

University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali
- 140413, India

Akshay Dahiya

University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali
- 140413, India

Lakhwinder Singh

University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali
- 140413, India

Rajeev Garg

University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali
- 140413, India

Corresponding author email: rajeev.e11793@cumail.in

Abstract--Liposomes or lipid vesicles were discovered by hydration of a self-forming encapsulated lipid bilayer; liposome drug delivery methods have played an important part in the development of effective pharmaceuticals to enhance treatments. Liposomes are spherical vesicles made up of one or more lipid bilayers with an aqueous compartment in the middle. Liposome is an abbreviation for "lipid body." It derives from the name of sub cellular particles known as ribosome. A.D. Bangham created the first liposomes in the early 1960s. Their dimensions range between 25 and 500nm. They are now an extremely valuable tool in a variety of scientific areas, including chemistry, colloid science, biochemistry, biology, and pharmaceutical research. Liposomes are a distinct and advanced technique for transporting active compounds to the site of action, and numerous dosage forms are already in clinical use. This study outlines the categorization, techniques of synthesis, stability, and applications of liposomal drug formulations.

Keywords--Liposome-based drug delivery method, Liposome structural components, Liposome fabrication methods.

Introduction

Paul Ehrlich introduced the time of designated conveyance in 1906 when he proposed a therapeutic conveyance strategy that would course sedates straightforwardly to harmed cells, which he named "enchantment slugs"^[1-4]. "Liposome's are colloidal, vesicular structures consisting of one or more lipid bilayers enclosing an equal number of aqueous compartments," according to this definition. Shell like circle encased a fluid inside that included peptides and proteins, chemicals, catalysts, anti-toxins, antifungal, and anticancer mixtures, in addition to other things. Due to metabolism and elimination, a free medication injected into the bloodstream normally achieves therapeutic levels for only a brief time. The circle like shell encased a fluid inside that included peptides and proteins, chemicals, catalysts, anti-toxins, antifungal, and anticancer mixtures, in addition to other things^[5, 6].

Advantages of liposomes [7, 9, 11-16]

- Liposomes made by encapsulation have better stability.
- Liposomes improved a drug's effectiveness and therapeutic index (actinomycin-D).
- Liposomes lower the encapsulated agent's toxicity (amphotericin B, Taxol).
- Liposomes aid in the reduction of hazardous drug exposure to sensitive tissues.
- The impact of avoiding a certain location.
- For fundamental and non-fundamental portions, Liposomes are versatile, nonhazardous, nanocomposite, completely eco-friendly & immune-inhibitive.

Disadvantages [7, 8, 10, 12-17]

- It has a short half-life.
- Solubility is low.
- Encapsulated drug/molecule leakage and fusion
- The cost of manufacture is expensive.
- Phospholipids can be oxidized and undergo a hydrolysis-like process.
- Procedure takes a long time.
- There are fewer steadinesses.
- Liposomal components can cause allergic responses.

Types of liposomes ^[1-6]

Liposomes are categorized according to their size.

A) Structural parameters are used:

1. *Vesicles that are unilamellar:*

- Little uni-lamellar vesicles (SUV) range in diameter of 20 to 40 nanometers.
- Medium unilamellar vesicles (MUVs) range in diameter of 40 to 80 nanometers.
- LUVs (large unilamellar vesicles): They are 100 to 1,000 nanometers in sizes.

2. *Oligo-lamellar vesicles (OLV):*

OLV are composed of 2 to 10 lipid bi-layers that surround a massive internal volume. There are a few bi-layers in MLVs (multi-lamellar vesicles). They have an endless number of methods to compartmentalize the aqueous volume. They are differentiated by how they are cooked. The designs can be onion-like, for example, with concentric circular bi-layers of LUV/MLV enveloping a massive quantity of SUV.

B) Based on method of preparation of Liposomes

1. REV: Single or oligolamellar vesicles are produced via reverse-phase evaporation.
2. MLV-REV: Multilamellar Vesicles Reverse-Phase Evaporation Method
3. SPLV is an abbreviation for Stable Plurilamellar Vesicles.
4. Frozen & Thawed MLV is an abbreviation of FATMLV.
5. VET: Extrusion-produced vesicles.
6. Dehydration-rehydration is abbreviated as DRV.

C) Composition and application-based

1. Conventional liposomes are composed of neutral or cholesterol, as well as negatively charged phospholipids (CL).
2. Fusogenic Liposomes derived from reconstituted Sendai virus envelopes (RSVE).
3. Liposomes containing pH-sensitive phospholipids, such as PE or DOPE in combination with CHEMS or OA.
4. DOPE-coated cationic lipids in cationic liposomes
5. Long Circulatory Liposomes (Stealth) (LCL): To reduce phagocyte detection, polyethylene glycol (PEG) derivatives are attached to the surface of these liposomes (reticuloendothelial system; RES). When PEG is added to liposomes, it inhibits their clearance from the bloodstream and increases their circulation throughout the body. Pegylation is the process of attaching PEG to another substance.
6. Immuno-Liposomes are CL or LCL that include monoclonal antibodies or recognition sequences.

Method of preparation of liposomes General methods of preparation

General methods of preparation of liposomes are of 4 main phases:

1. Extracting and drying lipids from a natural dissolvable.
2. Lipid scattering in watery medium
3. Purifying the liposome that outcomes.
3. Examining the finished result.

Method of preparation of liposomes and drug loading Liposomes are prepared using the methods listed below:

1. Loading strategies that are passive
2. The active loading technique.

Passive loading methods are classified into three types:

1. Method of mechanical dispersion
2. Method of solvent dispersion

3. Technique of detergent removal (exclusion of non-encapsulated material).
[18,19]

Method of mechanical dispersion

Mechanical dispersion methods include the following:

1. Sonication.
2. Extrusion in a French pressure cell.
3. Freeze-thawed liposomes
4. Hydration of lipid films by hand shaking, non-hand shaking, or freeze drying.
5. Micro-emulsification.
6. Extrusion of a membrane.
7. Reconstituted dried vesicles. [18,19]

Sonication The process of sonication is likely the most often employed for SUV preparation. Under a passive environment, MLVs are sonicated with a shower type sonicator or a test sonicator. The essential downsides of this approach are its restricted inside volume/epitome viability, the chance of phospholipids and compound corruption, the evacuation of enormous atoms, metal tainting from the test tip, and the presence of MLV along with SUV [18]. Sonication is classified into two categories:

- a) *Probe Sonication*. The tip of a sonicator is instantly immersed in the liposome dispersion. The quantity of energy dedicated to lipid dispersion in this strategy is tremendous. Because the coupling of energy at the tip creates localized heat, the vessel must be submerged in a water/ice bath. During sonication, more than 5% of the lipids can be de-esterified for up to 1 hour. Titanium will also peel off and pollute the solution when using the probe sonicator.
- b) *Bath sonication*. A cylinder of liposome dispersion is placed in a bath sonicator. Controlling the temperature of the lipid dispersion is often simpler with this procedure than with sonication by dispersal directly utilizing the tip. The material to be sonicated can be maintained safe in a sterile vessel separate from the probe units, or in an inert environment. [20].

French pressure cell: extrusion MLV is extruded through a tiny hole in a French pressure cell [18]. One of the advantages of the French press vesicle approach is that the proteins do not appear to be as pompous as they are during sonication [21]. A fascinating observation is that entrapped solutes in French press vesicles appear to be remembered substantially longer than SUVs generated by sonication or detergent removal [22-24]. The approach entails handling unstable materials with care. The approach provides a number of benefits over the sonication method [25]. Liposomes formed as a result are bigger than sonicated SUVs. The method's disadvantages are that the high temperature is difficult to achieve and that the working quantities are tiny (approximately 50 mL at most) [18,19].

Freeze-thawed liposomes SUVs are quickly frozen and then gently thawed. Sonication disperses aggregated materials to LUV in a short amount of time. The fusing of SUV during the freezing and thawing procedures results in the formation of unilamellar vesicles [26-28]. By raising the phospholipids content and the

medium's ionic strength, this kind of synthesis is significantly suppressed. Encapsulation efficiencies ranging from 20% to 30% were achieved. [26].

Solvent dispersion method

Ether injection (solvent vaporization) At 55°C to 65°C or under decreased pressure, a lipid solution mixed in diethyl ether or an ether-methanol combination is progressively injected into an aqueous solution of the substance to be encapsulated. Liposomes are formed as a result of the elimination of ether under vacuum. The technique's principal drawbacks are that the population is heterogeneous (70 to 200 nm) and that the chemicals to be encapsulated are exposed to organic solvents at high temperatures. [29,30].

Ethanol injection A lipid solution of ethanol is injected rapidly into a large amount of buffer. The MLVs are generated at the same time. The method's drawbacks include the population's heterogeneity (30 to 110 nm), the dilute nature of liposomes, the difficulty of removing all ethanol because it forms an azeotrope with water, and the high likelihood of biologically active macromolecules inactivating in the presence of even small amounts of ethanol. [31].

Detergent removal technique (removal of non-encapsulated material)

Dialysis To solubilize lipids, detergents were employed at their critical micelle concentrations (CMC). As the detergent is removed, the micelles grow more phospholipidrich and eventually unite to create LUVs. Dialysis was used to remove the detergents [32-34]. For the removal of detergents, a commercial equipment called LipoPrep (Diachema AG, Switzerland), which is a type of dialysis system, is available. Dialysis can be done in huge detergent-free buffers encased in dialysis bags (equilibrium dialysis) [35].

Detergent (cholate, alkyl glycoside, Triton X-100) removal of mixed micelles (absorption) Shaking a mixed micelle solution with beaded organic polystyrene absorbers such XAD-2 beads (SERVA Electrophoresis GmbH, Heidelberg, Germany) and Bio-beads SM2 achieves detergent absorption (Bio-Rad Laboratories, Inc., Hercules, USA). Detergent absorbers have the advantage of being able to remove detergents with a low CMC that aren't completely exhausted.

Active loading techniques

Proliposomes: This procedure included coating lipid and medication onto a soluble carrier to create a free-flowing granular substance in a pro-liposome, which when hydrated creates an isotonic liposomal solution. [36].

Lyophilization: Lyophilization is the process of removing water from frozen products at a low pressure. This approach is most commonly used to dry thermolabile materials.

Mechanism of action of liposomes

Liposomes use four different mechanisms to carry out their functions. The following are the details:

- 1) *Endocytosis* The phagocytic cells of the reticuloendothelial framework, like neutrophils, are liable for this. [37].
- 2) *Adsorption* — Vague electrostatic powers or cooperation's with cell surface parts make harm the cell surface. [38].
- 3) *Fusion*- It occurs when a liposomal bilayer is inserted into the plasma membrane and the liposomal content is continuously released into the cytoplasm. [39].
- 4) *Lipid exchange*- Liposomal lipids are transferred to the cellular membrane without liposomal contents being associated. [40].

Purification of liposomes

Liposome purification methods include gel filtration chromatography, dialysis, and centrifugation. The most generally utilized chromatographic partition material is Sephadex50. In the dialysis activity, an empty fiber dialysis cartridge can be utilized. SUVs in ordinary saline can be isolated utilizing the centrifugation approach, which incorporates centrifuging at 200000 g for 10-20 hours. MLVs are disengaged by centrifuging for under an hour at 100000 g. [41, 42]

Evaluation of liposomes [42-46]

The definition and handling of liposomes for a particular application are depicted to guarantee unsurprising in vivo and in vitro execution. The three primary types of characterization boundaries for assessment purposes are physical, synthetic, and natural elements.

- Actual characterization examines, among other things, size, shape, surface features, lamellarity, stage behaviour, and medicine discharge profile.
- Substance characterisation alludes to examinations that decide the immaculateness and intensity of various lipophilic fixings.
- Organic characterisation factors help in deciding the detailing's wellbeing and suitability for remedial use.

Some of limits are:

Lamellarity and vesicle shape: Electron infinitesimal methods can be utilized to assess vesicle shape. FFE Microscopy and P-31 NMR Analysis are utilized to quantify the lamellarity of vesicles, or the quantity of bi-layers present in liposomes.

Size and dispersion of vesicles: Various methodologies for estimating size and size distribution are reported in the literature. Light Microscopy, Fluorescent Microscopy, Electron Microscopy (especially TEM), Laser light dispersion Photon connection Spectroscopy, Field Flow Fractionation, Gel Permeation, and Gel Exclusion are a few of the methods accessible. Electron microscopy is the most

exact approach for evaluating liposome size since it allows you to view each individual liposome and collect precise statistics on the liposome population's features throughout a wide range of sizes. Regrettably, it takes up the most of the day and necessitates gear that isn't always readily available. The laser light dispersal approach, on the other hand, is extremely easy and quick to use, but it has the limitation of not determining the usual attribute of the heft of liposomes. These approaches necessitate the purchase of expensive gear. Gel avoidance chromatography approaches are illustrated with the assumption that just a rough understanding of size range is desired, as the only costs are supports and gel material. Liposome structure, size, and security have been studied using nuclear power microscopy, a more recently developed minute technology. The majority of tactics used in size, shape, and circulation focus on fall into one of four categories: small, diffraction, scattering, and hydrodynamic.

Microscopic techniques

Optical Microscopy: The microscopic approach, which involves the use of a phase contrast, bright-field, and fluorescent microscope, is excellent for determining the size of big vesicles.

Negative Stain TEM: Electron Microscopy is a word that refers to the study of electrons in a Negative-stain environment. The most extensively used methods for determining liposome form and size are transmission electron microscopy (TEM) and scanning electron microscopy (SEM). The final plan is less well-known. The Negative Stain has a Electron microscopy is used to detect bright areas against a dark backdrop (henceforth named as bad stain) As unpleasant stains in TEM examination, ammonium molybdate, phosphotungstic corrosive (PTA), or uranyl acetic acid derivation are used. PTA and ammonium molybdate are both anionic mixes, however the derivation of uranyl acetic acid is cationic.

- a. *Techniques for cryo-transmission electron microscopy (cryo-tem):* The surface appearance and vesicles size have been clarified using this approach.
- b. *Techniques for diffraction and scattering*

Laser-light scattering: PCS is the study of the time dependence of power variations in dissipated laser light caused by Brownian motion of particles in arrangement or suspension. Large particles doesn't scatter quicker than little particles, henceforth the pace of progress in dissipated light force fluctuates relatively. The translational dissemination coefficient (D) may then be determined utilizing the Stoke-Einstein condition to get the mean hydrodynamic range (Rh) of particles. This approach might be utilized to evaluate particles in the 3nm territory. 2.

Hydro-dynamic Techniques: This approach employs two procedures: gel permeation and ultracentrifugation. To recognize SUVs from outspread MLVs, prohibition chromatography on huge unadulterated gels was utilized. Gel Permeation and Ultracentrifuge are two techniques used in this method. Exclusion chromatography on large pure gels was utilised to differentiate SUVs from radial MLVs. A thin layer chromatography framework in view of agarose dabs has been created as a helpful and speedy strategy for assessing the size conveyance of liposome arrangements. Nonetheless, it was not communicated

expecting this approach was weak to a genuine square of agarose gel pores, very much like the case with more standard fragment chromatography.

Trapped Volume & Encapsulation Efficiency

The total and rate of ensnarement of water solvent compounds in the watery compartment are not fixed by these factors.

a) *Encapsulation efficiency*: It is generally specified as percent capture/mg lipid and refers to the level of the watery stage, and hence the level of water solvent medication, that becomes captured during liposome assembly. Mini-column centrifugation and Pro-tamine collection are used to determine epitome viability. Mini-column centrifugation is commonly used on a small scale to sanitise and divide liposomes. In the small segment centrifugation strategy, the hydrated-gel is placed in a 1 ml 'needle barrel' without an unclogged and stopped with a Whitman GF/B channel cushion. This barrel is resting inside an axis tube. To eliminate any residual saline arrangement from the gel, turn this cylinder for 3 minutes at 2000 rpm. The gel part should be dry and detached from the barrel's side after centrifugation. From that moment forward, the collecting tube is drained of eluted saline. A drowse 0.2ml Liposome suspension is injected to the highest point of the gel bed, and the section is spun at 2000 rpm for 3 minutes to expel the liposome-containing void volume into the centrifuge tube. The elute is then isolated and stored for further testing. The pro-tamine accumulation approach is applicable to both neutral and negatively charged liposomes.

b) *Trapped volume*: It is a critical barrier that regulates vesicle shape. The caught volume, also known as the internal volume, is the amount of water entrapped per unit amount of lipids. This might range between 0.5 and 30 microlitres per micromol. To estimate caught/inside volume, a few components such as "spectroscopically inactive fluids, radioactive markers, and fluorescent markers" are used. The easiest way to determine inner volume is to directly measure the quantity of water by substituting a spectroscopically inactive liquid (deuterium-oxide) for the outer medium (H₂O) and then using NMR to verify the water signal. The captured volume may also be estimated provisionally by spreading lipid in a watery solution containing a non-porous radioactive component. . The amount of solute captured is measured by centrifugation to exclude outside radioactivity, and then lingering movement is not totally fixed.

Transitional behavior and phase response

Liposomes and lipid bilayers go through a number of phase changes that are being studied for their role in activating medication release or stimulating liposomal component fusion with target cells. Phase transitions and the fluidity of phospholipid membranes are crucial in the production and usage of liposomes since the phase behaviour of the liposomal membrane controls properties such as "permeability, fusion, aggregation, and protein binding". Frozen fracture electron microscopy was used to assess the phase transition. Differential scanning calorimeter (DSC) study provides a more thorough verification.

Drug release

A very much adjusted in-vitro dissemination cell can be utilized to explore the course of medication discharge from liposomes. In vitro experiments can be used to evaluate the pharmacokinetics and bio-availability of a liposome-based strategy before doing costly and time-consuming in vivo research. The pharmacokinetic execution of liposomal details was anticipated utilizing weakening actuated medication discharge in support and plasma, and the bioavailability of the medication was resolved to utilize a test that deliberate intra-cellular medication discharge prompted by liposome corruption within the sight of "mouse-liver lysosome-lysate".

Targeting of liposomes [46-51]

There are two sorts of targeting.

Passive targeting

Such regularly delivered liposomes have been found to be rapidly removed from the circulatory system and picked up by the RES in the liver and spleen as an inactive focusing technique. When liposomes are introduced to macrophages, their ability may be used. This has been established by the effective delivery of liposomal antimicrobial medicines to macrophages. Liposomes have been utilized to target antigens to macrophages at an early step in the enhancement of invulnerability. In rats, for example, i.v. infusion of liposomal antigen elicited a "spleen phagocyte-intervened" counteracting agent reaction, whereas non liposome related antigen elicited no neutralizer reaction.

Active targeting

The emphasis on experts should be placed on the liposomal surface so that communication with the target, that is, 'the receptor,' may be categorised as a fitting and attachment mechanism. The liposome is designed in such a way that the lipophilic component of the association is cemented into the layer during film formation. In order to connect with the phone's receptor, the hydrophilic part of the liposome's surface where the targeting specialized is placed must be kept in a sterically proper position. Dynamic focusing is a technique that can be used.

Immuno liposomes: These ordinary or secretive liposomes are connected to antibodies or other recognition structures [for example, starch determinants such as glycoprotein]. The immune response binds to the liposome and guides it to certain antigenic-receptors on the cell. Glycolipids and glycoprotein are cell surface components that help cells recognize and connect with one another. *ii. Magnetic liposomes:* Attractive iron-oxide is available. An outer swaying attractive field in the conveyance areas of these liposomes can guide them.

Temperature and heat sensitive liposomes: These are designed to have a temperature change that is merely above the internal heat level. Remotely warmed the spot in the wake of showing up to deliver the prescription.

Applications ^[51]

- Chemotherapy for disease
- Quality treatment
- Liposomes as antibody transporters
- Liposomes as medication transporters in oral-treatment
- Liposomes for “pneumonic conveyance”
- Leishmaniasis prevention
- Lysosomal capacity infection
- Cell organic application
- Metal stockpiling infection
- Ophthalmic medicine conveyance

Topical drug delivery system

A skin conveyance framework is the substance that delivers a specific drug into touch with and through the skin. The transfer of topical drugs over the epidermal barrier is a difficulty. There are two essential sorts of effective conveyance items: External topical are applied to the coetaneous tissues and distributed, sprayed, or otherwise disseminated to cover the afflicted region. Inner topical with neighborhood action that are administered orally, vaginally, or on anorectal tissues to the mucous film. Skin meds are generally normally used for restricted impacts at the application site because of drug infiltration into the fundamental layers of skin or mucous films. Albeit some unintentional prescription assimilation might happen, it is generally in limited quantities and is of little importance.

Benefits of topical medication delivery systems ^[52-55]

The first pass metabolism is avoided. It's convenient and simple to use. Avoiding the dangers and drawbacks of intravenous treatment, as well as a variety of absorption circumstances such as pH fluctuations, enzyme-presence, and stomach emptying time. When the time comes, you can easily stop taking the drugs. Convey the medication to a predetermined area with more prominent accuracy. Gastrointestinal contrariness is avoided. Considering the use of drugs having a short organic half-life and a limited therapeutic window. Patient compliance has improved. Ensure that self-medication is possible. Continuous medication input allows for greater efficacy with a lower total daily dosage of medicine. Prevents medication level fluctuations, as well as differences between and within patients. In compared to the buccal cavity, the application area is fairly vast. Ability to administer medications to a specific location more selectively.

Disadvantages of topical medication delivery systems

The medication or its excipients may cause skin bothering or dermatitis. A few medications have a low piousness via the skin. Drugs with larger molecular sizes are more difficult to absorb through the skin. Hypersensitive responses are plausible. 5 Can only be used for medications that require a very low plasma concentration to work. Drugs that bother or sharpen the skin are not appropriate for this strategy. ^[52,55,56]

Classification of gels

Gels are classed on the basis of colloidal phases, solvent type, physical and rheological characteristics, and so forth.

Based on colloidal phases

They are classed as follows:

a. Two- phase system i.e. inorganic

If the dispersed phase partition size is large and develops a 3-D structure throughout the gel, the system will be made up of floccules of tiny particles rather than larger molecules, and the gel structure will be unstable. They must be thixotropic, which means that they form a semisolid while un-agitated and turn liquid when agitated. Al₂O₃ and bentonite magma are two examples.

b. Single phase system i.e. organic

These are big organic molecules that are continuously dissolved on the twisted threads in a continuous phase. The majority of organic gels are single-phase solutions made up of gelling chemicals like tragacanth, Carbomer & organic liquids like Plastibase.

Based on nature of the solvent

Hydrogels (water- based)

A hydrogel is a threedimensional network of hydrophilic polymers that can expand in water and contain a considerable quantity of water while maintaining their structure due to the chemical or physical cross-linking of individual polymer chains. Hydrophilic colloids such as “silica, bentonite, tragacanth, pectin, sodium alginate” and others are examples of such colloids. The hydrogel can be employed for prolonged medication release, rectal drug administration, and ECG medical electrodes.

Organogels (with a non-aqueous solvent)

An organogel is a type of gel that consists of a liquid organic phase surrounded by a 3D & cross-linked network. The insertion of a polar solvent causes organo gelling & gelation of lecithin solution in organic solvents.

Application of gel^[57]

As medication delivery devices for pharmaceuticals that are taken orally. To administer a topical medicine to the skin, eye, or mucous membrane directly. Intramuscular injections of long-acting drugs. Shampoos, aroma items, dentifrices, and skin and hair care arrangements are instances of beauty care products.

Characteristics of gels^[58,59]

Swelling: While a gelling specialist is in contact with a solvating fluid, the specialized absorbs a large amount of fluid, making the volume develop. This is

alluded to as enlarging. This occurs because of the dissolvable entering the lattice.

Syneresis: On standing, many gels pack precipitously and discharge a liquid medium. Syneresis is the term for this peculiarity. As the centralization of gelling specialist falls, the level of Syneresis increments.

Ageing: Colloidal systems are known for their sluggish aggregation. Ageing is the term for this process. In gels, the gelling ingredient gradually forms a denser network as it ages.

Structure: The existence of an organisation brought about by the inter-linking of gelling specialised particles results in the solidity of a gel. Straighten out the particle's nature and the tension, and the resistance to flow will be reduced.

Rheology: The gelling agent solutions and flocculated material dispersion are pseudo plastic in character, meaning they follow Non-Newtonian flow behaviour, which is characterized by a decrease in viscosity as the shear rate increases.

Liposomal gels formulation with different drugs

“Formulation of Topical Liposomal Gel for Fluconazole”

To assist fluconazole molecules in the epidermal layers, liposomal carriers, which are well recognised for their potential in topical drug administration, were chosen. The formulation of liposomes for effective fluconazole organization was finished utilizing a factorial plan strategy. Phospholipids PL 90H and CH (cholesterol) concentrations were estimated at 3 distinct levels, and liposomes were made utilizing the film-hydration technique. In Carbopol® 934 NF, liposome-containing gels (optimised batch) were made and assessed in the rat skin for rheology, spreadability, penetration, and drug deposition. The results of regression analysis demonstrated that cholesterol and lipid content influenced vesicle size and entrapment efficiency. All liposomal gels made with 1 percent, 1.5 percent, and 2 percent w/w carbopol were studied rheologically to determine the carbopol concentration necessary. When compared to a control and a commercially available gel, liposomal scattering and gels were displayed to expand skin entrance and statement. For 60 days, the liposome scattering and gel not set in stone to be steady.^[60]

“Formulation of a topical liposomal gel containing a combination of zedoary turmeric oil and tretinoin for psoriasis activity”

A topical medication delivery method combining zedoary turmeric oil (ZTO) and tretinoin (TRE)-loaded liposomal gel. To comprehensively improve the encapsulation process of compound liposomes, we employed a mix of single factor and orthogonal experiments. Continuous in vitro (skin penetration and retention) and in vivo (anti-psoriatic action utilising mouse vaginal model and mouse tail model) investigations were conducted using the improved liposome vesicles inserted into Carbopol gel matrix. The optimised liposomes showed an entrapment efficiency (EE) of 64.63 1.00 percent, a TRE EE of 90.33 0.72 percent, a ZTO drug loading (DL) of 9.09 0.14%, a TRE DL of (1.43 0.02) percent, a particle size of 257.41 7.58 nm, a polydispersity index (PDI) of 0.10 0.04, and a zeta potential of -38 Liposomes exhibited a consistent spherical surface, according to transmission electron microscopy. The improved liposome formulations were

stable after a month of storage at (4 ± 2) °C. In an in vitro investigation, liposome formulations were found to dramatically extend drug penetration into mouse hair follicles and preserve more pharmaceuticals in the skin than traditional gel formulations. Liposomal gel was found to be more successful than conventional gel in treating psoriasis in an in vivo research, with a substantial dose-dependent effect on psoriasis. In conclusion, liposomal gel is predicted to be a suitable carrier for ZTO and TRE topical drug delivery systems.^[61]

“Liposomal gels for vaginal drug delivery”

The goal of our research was to create a liposomal drug carrier system that could deliver a prolonged and regulated release of a local vaginal treatment medication. Liposomes containing calcein were synthesised using five different ways in order to optimise the size and entrapment efficiency of the liposomes. In vitro stability of two ideal liposomal preparations (proliposomes and polyol dilution liposomes) was investigated in environments that mimicked human vaginal circumstances (buffer, pH 4.5). Liposomes were combined into vehicles suited for vaginal self-administration to bring them closer to in vivo use and to increase their stability. For liposomal preparations, polyacrylate gels were employed as vehicles. It was achievable to attain an adequate pH value matching to physiological circumstances as well as desirable viscosity thanks to their hydrophilic nature and bioadhesive characteristics. Liposomes contained in these gels (Carbopol 974P NF or Carbopol 980 NF) were tested in vitro for their suitability as a new medication carrier system for vaginal administration. Regardless of the gel utilised, more than 80% of the originally entrapped material was still preserved 24 hours following incubation of liposomal gel in buffer pH 4.5. All rights reserved 2001 Elsevier Science B.V.^[62]

“Flexible liposomal gel dual-loaded with all-trans retinoic acid and betamethasone for enhanced therapeutic efficiency of psoriasis”

Psoriasis is an inflammatory skin condition caused by the immune system that has no cure. Due to their relatively low stability, limited skin penetration, and systemic adverse effects, the use of all transretinoic acid (TRA) and betamethasone (BT) for the treatment of psoriasis is still a challenge. Flexible liposomes are good at penetrating deeper into the skin and decreasing medication side effects, which bodes well for the successful treatment of skin problems. The goal of this study was to develop a dual-loaded flexible liposomal gel based on TRA and BT for improved psoriasis treatment efficiency. ^[63]

Conclusions

Liposomes have been demonstrated to be extraordinarily powerful transporters for designated prescription conveyance. The versatility of their behaviour might be used to handle drugs by any branch of the corporation & to any prescription material, paying little heed to solvency characteristics. The use of liposomes as a carrier for prescriptions and attributes is promising and will most likely continue to advance in the future.

References

1. Alving CR. Macrophages, as targets for delivery of liposome encapsulated antimicrobial agents. *Adv Drug Deliv Rev.* 1988;2(1):107-28. doi: [10.1016/0169409X\(88\)90007-5](https://doi.org/10.1016/0169409X(88)90007-5).
2. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. *Curr Drug Deliv.* 2007;4(4):297-305. doi: [10.2174/156720107782151269](https://doi.org/10.2174/156720107782151269), PMID [17979650](https://pubmed.ncbi.nlm.nih.gov/17979650/).
3. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. *Nature.* 1974;252(5480):252. doi: [10.1038/252252a0](https://doi.org/10.1038/252252a0), PMID [4424229](https://pubmed.ncbi.nlm.nih.gov/4424229/).
4. Mufamadi MS et al. A Rev won Composite liposomal Technologies for Specialized Drug Delivery. *J Drug Deliv.* 2011:1-19.
5. Deamer D, Uster P. Liposome preparation methods and monitoring liposome fusion. In: Baserga R, Croce C, Royeza G, editors, *Introduction of Macromolecules into viable Mammalian Cells*. Vol. 205. New York: Alan R Liss; 1980,pp. p. 220.
6. de Marie S, Janknegt R, Bakker-Woudenberg IAJM. Clinical use of liposomal and lipid-complexed amphotericin B. *J Antimicrob Chemother.* 1994;33(5):907-16. doi: [10.1093/jac/33.5.907](https://doi.org/10.1093/jac/33.5.907), PMID [8089064](https://pubmed.ncbi.nlm.nih.gov/8089064/).
7. Shashi K et al. 'A complete Rev on Liposomes' *IRJP.* 2012;3(7):10-6.
8. Mufamadi MS et al. A Rev won Composite liposomal Technologies for Specialized Drug Delivery. *J Drug Deliv.* 2011:1-19.
9. Marrispati S et al. A rev on liposome. *Int J Res Pharm Nano Sci.* 2014;3(3):159-69.
10. Bulbake U et al. Liposomal formulations in clinical use: an updated rev. *Pharm.* 2017;9(12):1-33.
11. Kalepu S et al. Liposomal drug delivery system - A Comprehensive Rev. *Int J Drug Dev Res.* 2013;5(4):62-75.
12. Sharma D et al. An Updated Rev on liposomes as drug delivery system. *PharmaciaTutor.* 2018;6(2):4962.
13. Uhumwangho MU, Okor RS. Current trends in the production and biomedical applications of liposomes: A Review. *J Med Biomed Res.* 2005;4(1):9-21. doi: [10.4314/jmbr.v4i1.10663](https://doi.org/10.4314/jmbr.v4i1.10663).
14. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. Liposome: classification, preparation, and applications. *Nanoscale Res Lett.* 2013;8(1):102. doi: [10.1186/1556-276X-8-102](https://doi.org/10.1186/1556-276X-8-102), PMID [23432972](https://pubmed.ncbi.nlm.nih.gov/23432972/).
15. Yadav AV et al. Stability aspects of liposomes. *Ind J Pharm Educ Res.* 2011;45(4):402-13.
16. Alavi M, Karimi N, Safaei M. Application of various types of liposomes in drug delivery systems. *Adv Pharm Bull.* 2017;7(1):3-9. doi: [10.15171/apb.2017.002](https://doi.org/10.15171/apb.2017.002), PMID [28507932](https://pubmed.ncbi.nlm.nih.gov/28507932/).
17. Bodke AR et al. A rev on liposomes. *Int J Pharm Chem Res.* 2017;3(2):120-7.
18. Riaz M. Liposome preparation method. *Pak J Pharm Sci.* 1996;9(1):65-77. PMID [16414777](https://pubmed.ncbi.nlm.nih.gov/16414777/).
19. Himanshu A, Sitasharan P, Singhai AK. Liposomes as drug carriers. *IJPLS.* 2011;2(7):945-51.
20. Kataria S, Sandhu P, Bilandi A, Akanksha M, Kapoor B, Seth GL, Bihani SD. Stealth liposomes: a review. *IJRAP.* 2011;2(5):1534-8.

21. Mayer LD, Bally MB, Hope MJ, Cullis PR. Techniques for encapsulating bioactive agents in to liposomes. *Chem Phys Lipids*. 1986;40(2-4):333-45. doi: [10.1016/0009-3084\(86\)90077-0](https://doi.org/10.1016/0009-3084(86)90077-0), PMID [3742676](https://pubmed.ncbi.nlm.nih.gov/3742676/).
22. Song H, Geng HQ, Ruan J, Wang K, Bao CC, Wang J, Peng X, Zhang XQ, Cui DX. Development of polysorbate 80/phospholipid mixed micellar formation for docetaxel and assessment of its in vivo distribution in animal models. *Nanoscale Res Lett*. 2011;6(1):354. doi: [10.1186/1556-276X-6-354](https://doi.org/10.1186/1556-276X-6-354), PMID [21711889](https://pubmed.ncbi.nlm.nih.gov/21711889/).
23. Zhang Y. Relations between size and function of substance particles. *Nano Biomed Eng*. 2011;3(1):1-16.
24. Mozafari MR. Liposomes: an overview of manufacturing techniques. *Cell Mol Biol Lett*. 2005;10(4):711-9. PMID [16341279](https://pubmed.ncbi.nlm.nih.gov/16341279/).
25. Hamilton RL, Guo LSS. Liposomes preparation methods. *J Clin Biochem Nutr*. 1984;7:175.
26. Pick U. Liposomes with a large trapping capacity prepared by freezing and thawing of sonicated phospholipid mixtures. *Arch Biochem Biophys*. 1981;212(1):186-94. doi: [10.1016/0003-9861\(81\)90358-1](https://doi.org/10.1016/0003-9861(81)90358-1), PMID [7197900](https://pubmed.ncbi.nlm.nih.gov/7197900/).
27. Ohsawa T, Miura H, Harada K. Improvement of encapsulation efficiency of water-soluble drugs in liposomes formed by the freeze-thawing method. *Chem Pharm Bull (Tokyo)*. 1985;33(9):3945-52. doi: [10.1248/cpb.33.3945](https://doi.org/10.1248/cpb.33.3945), PMID [4092294](https://pubmed.ncbi.nlm.nih.gov/4092294/).
28. Liu L, Yonetani T. Preparation and characterization of liposome encapsulated haemoglobin by a freeze-thaw method. *J Microencapsul*. 1994;11(4):409-21. doi: [10.3109/02652049409034258](https://doi.org/10.3109/02652049409034258), PMID [7931940](https://pubmed.ncbi.nlm.nih.gov/7931940/).
29. Deamer D, Bangham AD. Large volume liposomes by an ether vaporization method. *Biochim Biophys Acta*. 1976;443(3):629-34. doi: [10.1016/00052736\(76\)90483-1](https://doi.org/10.1016/00052736(76)90483-1), PMID [963074](https://pubmed.ncbi.nlm.nih.gov/963074/).
30. Schieren H, Rudolph S, Finkelstein M, Coleman P, Weissmann G. Comparison of large unilamellar vesicles prepared by a petroleum ether vaporization method with multilamellar vesicles: ESR, diffusion and entrapment analyses. *Biochim Biophys Acta*. 1978;542(1):137-53. doi: [10.1016/0304-4165\(78\)90240-4](https://doi.org/10.1016/0304-4165(78)90240-4), PMID [208648](https://pubmed.ncbi.nlm.nih.gov/208648/).
31. Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. *Biochim Biophys Acta*. 1973;298(4):1015-9. doi: [10.1016/0005-2736\(73\)90408-2](https://doi.org/10.1016/0005-2736(73)90408-2), PMID [4738145](https://pubmed.ncbi.nlm.nih.gov/4738145/).
32. Daemen T, Hofstede G, Ten Kate MT, Bakker-Woudenberg IAJM, Scherphof GL. Liposomal doxorubicin induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. *Int J Cancer*. 1995;61(5):716-21. doi: [10.1002/ijc.2910610520](https://doi.org/10.1002/ijc.2910610520), PMID [7768646](https://pubmed.ncbi.nlm.nih.gov/7768646/).
33. Kirby CJ, Gregoriadis G. A simple procedure for preparing liposomes capable of high encapsulation efficiency under mild conditions. In: Boca Raton GG, editor. *Liposome Technology*. 1st ed. CRC Press; 1984. p. 19-27.
34. Alpes H, Allmann K, Plattner H, Reichert J, Rick R, Schulz S. Formation of large unilamellar vesicles using alkyl maltoside detergents. *Biochim Biophys Acta*. 1986;862(2):294-302. doi: [10.1016/0005-2736\(86\)90231-2](https://doi.org/10.1016/0005-2736(86)90231-2).

35. Shaheen SM, . FRSA, . MNH, . MA, . MSA, . MA. Liposome as a carrier for advanced drug delivery. *Pak J Biol Sci.* 2006;9(6):1181-91. doi: [10.3923/pjbs.2006.1181.1191](https://doi.org/10.3923/pjbs.2006.1181.1191).
36. John DF, Yunus AA, Chigbo UJ, Paul US, Ikenna E. Tolnaftate loaded liposomes design, and in-vitro evaluation. *Univers J Pharm Res.* 2016;1(2):48-53. doi: [10.22270/ujpr.v1i2.R6](https://doi.org/10.22270/ujpr.v1i2.R6).
37. Kaur D, Kumar S. Niosomes: present scenario and future aspects. *J Drug Deliv Ther.* 2018;8(5):35-43. doi: [10.22270/jddt.v8i5.1886](https://doi.org/10.22270/jddt.v8i5.1886).
38. Hong MS, Lim SJ, Lee MK, Kim YB, Kim CK. Prolonged blood circulation of methotrexate by modulation of liposomal composition. *Drug Deliv.* 2001;8(4):231-7. doi: [10.1080/107175401317245912](https://doi.org/10.1080/107175401317245912), PMID [11757781](https://pubmed.ncbi.nlm.nih.gov/11757781/).
39. al Jesorka A, Orwar O. Liposomes: technologies and analytical applications. *Annu Rev Anal Chem (Palo Alto Calif).* 2008;1:801-32. doi: [10.1146/annurev.anchem.1.031207.112747](https://doi.org/10.1146/annurev.anchem.1.031207.112747), PMID [20636098](https://pubmed.ncbi.nlm.nih.gov/20636098/).
40. Vemuri S, Rhodes CT. Preparation and characterization of liposomes as therapeutic delivery systems: a review. *Pharm Acta Helv.* 1995;70(2):95-111. doi: [10.1016/0031-6865\(95\)00010-7](https://doi.org/10.1016/0031-6865(95)00010-7), PMID [7651973](https://pubmed.ncbi.nlm.nih.gov/7651973/).
41. Jr. F. Szoka and D. Papahadjopoulos. *Proc Natl Acad Sci U S A.* 1978;60:4194-8.
42. Jain NK. *Controlled and Novel drug delivery.* CBS Publisher, Page no. 304-326.
43. Kersten GFA, Crommelin DJA. Liposomes and ISCOMS as vaccine formulations. *Biochim Biophys Acta.* 1995;1241(2):117-38. doi: [10.1016/0304-4157\(95\)000029](https://doi.org/10.1016/0304-4157(95)000029), PMID [7640293](https://pubmed.ncbi.nlm.nih.gov/7640293/).
44. Horton K. *Disertation for degree of Advanced Studies in Chemical Engineering.* Universitat Rovira I Virgili; 2003.
45. Remington. *The science and practice of pharmacy.* Volume I. 21st ed, B.I Publishers Pvt Ltd. Page no. 314-316.
46. Leon S. *Applied biopharmaceutics and pharmacokinetics.* 5th ed. page no 214218.
47. Sharma. A. and Sharma *Liposomes in drug delivery progress and Limitations.* *Int J Pharm* page no 123,134-139.
48. Sharma A, Straubinger RM. Novel Taxol formulations: preparation and characterization of Taxol-containing liposomes. *Pharm Res.* 1994;11(6):889-96. doi: [10.1023/a:1018994111594](https://doi.org/10.1023/a:1018994111594), PMID [7937531](https://pubmed.ncbi.nlm.nih.gov/7937531/).
49. Szoka FC. Liposomal drug delivery: current status and future prospects. In: Wilschut J, Hoekstra D, editors, *Membrane.* New York: Fusion, Marcel Dekker; 1991. p. 845-90.
50. Vingerhoeds MH, Storm G, Crommelin DJA. Immunoliposomes in vivo. *Immunomethods.* 1994;4(3):259-72. doi: [10.1006/immu.1994.1028](https://doi.org/10.1006/immu.1994.1028), PMID [7820456](https://pubmed.ncbi.nlm.nih.gov/7820456/).
51. Vyas SP, Khar RK. *Targeted and Controlled Drug Delivery, Novel carrier system.* 1st ed. CBS Publisher. p. 173-206.
52. Kaur J, Kaur J, Jaiswal S, Gupta GD. Recent advances in topical drug delivery system. *Indo-American P'ceutical Re*2016; 6 (7);6876:2231.
53. Kaur LP, Guleri TK. Topical Gel: A Recent Approach for Novel Drug delivery. *Asian J biomedical P'ceutical Sci*2013; 3 (17):1-5.
54. Ahmed M, Ali M. Semisolid dosage form: topical gel formulation A review. *World J P'ceutical Res*2016; 5 (12):1256-1268.

55. Chittodiya P, Tomar RS, Ramchandani U, Manocha N, Agrawal. Topical gel - a review. *Int J P'ceutical& Biological Archives* .2013;4(4):606-13.
56. Patel RR, Patel KR, Patel MR. Formulation and Characterization of microemulsion based Gel of antifungal Drug, *Pharma Tutor*. 2014;2(2):79-89.
57. Krishna Sailaja A, Supraja R. et al. An overall review on topical preparation-gel: *Innovat. Int J Med P'ceutical Sciences*. 2016;1(1):17-20.
58. Roychowdhury S, Singh DH, Gupta R, Masih DA. Review on pharmaceutical gel. *Int J P'ceutical Rese Bio Scie*2012;1(5):2136.
59. Sharma B, Singh LR. Pharmaceutical gels for topical drug delivery: an overview. *Int. J Res Pharm P'ceutical Sci*. 2018;2:19-24.
60. Mitkari BV, Korde SA, Mahadik KR, Kokare CR. Formulation and evaluation of topical liposomal gel for fluconazole. *Indian J Pharm Educ Res*. 2010 Oct 1;44(4):324-33.
61. Chen J, Ma Y, Tao Y, Zhao X, Xiong Yongai, Chen Z, Tian Yingbiao. Formulation and evaluation of a topical liposomal gel containing a combination of zedoary turmeric oil and tretinoin for psoriasis activity. *J Liposome Res*. 2021;31(2):13044. doi: [10.1080/08982104.2020.1748646](https://doi.org/10.1080/08982104.2020.1748646), PMID [32223352](https://pubmed.ncbi.nlm.nih.gov/32223352/).
62. Pavelić Z, Škalko-Basnet N, Schubert R. Liposomal gels for vaginal drug delivery. *Int J Pharm*. 2001 May 21;219(1-2):139-49. doi: [10.1016/s0378-5173\(01\)006378](https://doi.org/10.1016/s0378-5173(01)006378), PMID [11337174](https://pubmed.ncbi.nlm.nih.gov/11337174/).
63. Wang W, Shu GF, Lu KJ, Xu XL, Sun MC, Qi J, Huang QL, Tan WQ, Du YZ. Flexible liposomal gel dual-loaded with all-trans retinoic acid and betamethasone for enhanced therapeutic efficiency of psoriasis. *J Nanobiotechnology*. 2020 Dec;18(1):1-4.